Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme

Advice programme

Showing 351 to 389 of 389

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Tirzepatide for managing overweight and obesity [ID6179]Technology appraisal guidance
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]Technology appraisal guidanceTBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]Technology appraisal guidanceTBC
Topical Antimicrobial dressings for wound care: Late stage assessmentHealth technology evaluation
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Total hip arthroplasty using the superpath approach for osteoarthritisInterventional procedures guidanceTBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]Technology appraisal guidanceTBC
Transcatheter heart valves for transcatheter aortic valve implantation in people with aortic stenosis: Late stage assessmentHealth technology evaluation
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]Technology appraisal guidanceTBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]Technology appraisal guidance
Treatments for non-small-cell lung cancer [ID6234]Technology appraisal guidanceTBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]Technology appraisal guidance
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]Technology appraisal guidanceTBC
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidance
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Type 2 diabetes in adults: management (medicines update)NICE guideline
Ublituximab for treating relapsing multiple sclerosis [ID6350]Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Urinary Tract Infection (recurrent): antimicrobial prescribingNICE guideline
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565Technology appraisal guidanceTBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Technology appraisal guidanceTBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vibegron for treating symptoms of overactive bladder ID6300Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Highly specialised technologyTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Women's and reproductive health guidelinesNICE guidelineTBC
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]Technology appraisal guidance
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Technology appraisal guidanceTBC
Zio XT for detecting cardiac arrhythmiasMedical technologies guidanceTBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]Technology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All